Palopegteriparatide (Yorvipath)
Canadian Journal of Health Technologies · 03.11.2026 · 6 (11)
DOI: 10.51731/cjht.2026.1563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 03.11.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses palopegteriparatide (Yorvipath) 168 mcg/0.56 mL, 294 mcg/0.98 mL, and 420 mcg/1.4 mL solution for subcutaneous injection. Indication: For the treatment of chronic hypoparathyroidism in adults.
Zitieren
APA
CDA-AMC (2026). Palopegteriparatide (Yorvipath). Canadian Journal of Health Technologies, 6(11). https://doi.org/10.51731/cjht.2026.1563
Vancouver
CDA-AMC. Palopegteriparatide (Yorvipath). Canadian Journal of Health Technologies. 2026;6(11). doi:10.51731/cjht.2026.1563
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Palopegteriparatide (Yorvipath)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {11},
doi = {10.51731/cjht.2026.1563}
}
EUVIMED